Literature DB >> 20951924

Clinical pharmacology of portal hypertension.

Cecilia Miñano1, Guadalupe Garcia-Tsao.   

Abstract

Portal hypertension is an increase in pressure in the portal vein and its tributaries. It is defined as a portal pressure gradient (the difference in pressure between the portal vein and the hepatic veins) greater than 5 mm Hg. Although this gradient defines portal hypertension, a gradient of 10 mm Hg or greater defines clinically significant portal hypertension, because this pressure gradient predicts the development of varices, decompensation of cirrhosis, and hepatocellular carcinoma. The most direct consequence of portal hypertension is the development of gastroesophageal varices that may rupture and lead to the development of variceal hemorrhage. This article reviews the pathophysiologic bases of the different pharmacologic treatments for portal hypertension in patients with cirrhosis and places them in the context of the natural history of varices and variceal hemorrhage. Published by Elsevier Inc.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20951924      PMCID: PMC3000670          DOI: 10.1016/j.gtc.2010.08.015

Source DB:  PubMed          Journal:  Gastroenterol Clin North Am        ISSN: 0889-8553            Impact factor:   3.806


  88 in total

1.  Beta-blockers to prevent gastroesophageal varices in patients with cirrhosis.

Authors:  Roberto J Groszmann; Guadalupe Garcia-Tsao; Jaime Bosch; Norman D Grace; Andrew K Burroughs; Ramon Planas; Angels Escorsell; Juan Carlos Garcia-Pagan; David Patch; Daniel S Matloff; Hong Gao; Robert Makuch
Journal:  N Engl J Med       Date:  2005-11-24       Impact factor: 91.245

2.  Variceal ligation plus nadolol compared with ligation for prophylaxis of variceal rebleeding: a multicenter trial.

Authors:  Joaquin de la Peña; Enric Brullet; Eloy Sanchez-Hernández; Monserrat Rivero; Mercedes Vergara; Jose Luis Martin-Lorente; Covadonga Garcia Suárez
Journal:  Hepatology       Date:  2005-03       Impact factor: 17.425

3.  Carvedilol, a new nonselective beta-blocker with intrinsic anti- Alpha1-adrenergic activity, has a greater portal hypotensive effect than propranolol in patients with cirrhosis.

Authors:  R Bañares; E Moitinho; B Piqueras; M Casado; J C García-Pagán; A de Diego; J Bosch
Journal:  Hepatology       Date:  1999-07       Impact factor: 17.425

4.  Acute and chronic haemodynamic and renal effects of carvedilol in patients with cirrhosis.

Authors:  A J Stanley; G Therapondos; A Helmy; P C Hayes
Journal:  J Hepatol       Date:  1999-03       Impact factor: 25.083

5.  Antibiotic prophylaxis for the prevention of bacterial infections in cirrhotic patients with gastrointestinal bleeding: a meta-analysis.

Authors:  B Bernard; J D Grangé; E N Khac; X Amiot; P Opolon; T Poynard
Journal:  Hepatology       Date:  1999-06       Impact factor: 17.425

6.  Inhibition of VEGF receptor-2 decreases the development of hyperdynamic splanchnic circulation and portal-systemic collateral vessels in portal hypertensive rats.

Authors:  Mercedes Fernandez; Marc Mejias; Bernhard Angermayr; Juan Carlos Garcia-Pagan; Juan Rodés; Jaime Bosch
Journal:  J Hepatol       Date:  2005-04-25       Impact factor: 25.083

7.  Randomized controlled trial of sclerotherapy versus somatostatin infusion in the prevention of early rebleeding following acute variceal hemorrhage in patients with cirrhosis. Variceal Bleeding Study Group.

Authors:  A Escorsell; J M Bordas; L R del Arbol; J L Jaramillo; R Planas; R Bañares; A Albillos; J Bosch
Journal:  J Hepatol       Date:  1998-11       Impact factor: 25.083

8.  Pharmacological reduction of portal pressure and long-term risk of first variceal bleeding in patients with cirrhosis.

Authors:  Juan Turnes; Juan Carlos Garcia-Pagan; Juan G Abraldes; Manuel Hernandez-Guerra; Alessandra Dell'Era; Jaime Bosch
Journal:  Am J Gastroenterol       Date:  2006-03       Impact factor: 10.864

9.  Propranolol plus prazosin compared with propranolol plus isosorbide-5-mononitrate in the treatment of portal hypertension.

Authors:  A Albillos; J C García-Pagán; J Iborra; J C Bandi; G Cacho; M Pérez-Paramo; A Escorsell; J L Calleja; P Escartín; J Bosch
Journal:  Gastroenterology       Date:  1998-07       Impact factor: 22.682

10.  Clinical vs haemodynamic response to drugs in portal hypertension.

Authors:  P A McCormick; D Patch; L Greenslade; J Chin; N McIntyre; A K Burroughs
Journal:  J Hepatol       Date:  1998-06       Impact factor: 25.083

View more
  20 in total

1.  Current Management Strategies for Acute Esophageal Variceal Hemorrhage.

Authors:  Brett Fortune; Guadalupe Garcia-Tsao
Journal:  Curr Hepatol Rep       Date:  2014-03-01

Review 2.  Pathophysiology and Management of Variceal Bleeding.

Authors:  Saleh A Alqahtani; Sunguk Jang
Journal:  Drugs       Date:  2021-03-12       Impact factor: 9.546

Review 3.  Treatment of portal hypertension.

Authors:  Khurram Bari; Guadalupe Garcia-Tsao
Journal:  World J Gastroenterol       Date:  2012-03-21       Impact factor: 5.742

4.  Future Pharmacological Therapies of Portal Hypertension.

Authors:  Guillermo A Ortiz; Guadalupe Garcia-Tsao
Journal:  Curr Hepatol Rep       Date:  2019-02-19

5.  Therapeutic potential of targeting the renin angiotensin system in portal hypertension.

Authors:  Chandana B Herath; Josephine A Grace; Peter W Angus
Journal:  World J Gastrointest Pathophysiol       Date:  2013-02-15

6.  N-acetylcysteine modulates angiogenesis and vasodilation in stomach such as DNA damage in blood of portal hypertensive rats.

Authors:  Francielli Licks; Renata Minuzzo Hartmann; Camila Marques; Elizângela Schemitt; Josieli Raskopf Colares; Mariana do Couto Soares; Juliana Reys; Camila Fisher; Juliana da Silva; Norma Possa Marroni
Journal:  World J Gastroenterol       Date:  2015-11-21       Impact factor: 5.742

7.  Combined Balloon-, Plug- and Coil-assisted Retrograde Transvenous Obliteration of Multiple Portosystemic Shunts to Treat Recurrent Hepatic Encephalopathy: A Case Report.

Authors:  Karan M Anandpara; Amar Mukund; Shiv K Sarin
Journal:  J Clin Exp Hepatol       Date:  2019-12-26

8.  Non-selective beta-blockers are not associated with serious infections in veterans with cirrhosis.

Authors:  J S Bajaj; S M Ratliff; D M Heuman; K L Lapane
Journal:  Aliment Pharmacol Ther       Date:  2013-06-20       Impact factor: 8.171

9.  Mapping metabolic brain activity in three models of hepatic encephalopathy.

Authors:  Natalia Arias; Marta Méndez; Camino Fidalgo; María Ángeles Aller; Jaime Arias; Jorge L Arias
Journal:  Int J Hypertens       Date:  2013-03-14       Impact factor: 2.420

10.  Zolmitriptan: a novel portal hypotensive agent which synergizes with propranolol in lowering portal pressure.

Authors:  Mercedes Reboredo; Haisul C Y Chang; Roberto Barbero; Carlos M Rodríguez-Ortigosa; Francisco Pérez-Vizcaíno; Asunción Morán; Mónica García; Jesús M Banales; Norberto Carreño; Félix Alegre; Ignacio Herrero; Jorge Quiroga; Jesús Prieto; Bruno Sangro
Journal:  PLoS One       Date:  2013-01-16       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.